A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species

Kelly Bohning, Stephanie Sonnberg, Hui-Ling Chen, Melissa Zahralban-Steele, Timothy Powell, Greg Hather, Hetal K. Patel, Hansi J. Dean

Takeda Vaccines, Inc., Cambridge, Massachusetts, United States of America

Abstract

Zika virus is a Flavivirus, transmitted via Aedes mosquitoes, that causes a range of symptoms including Zika congenital syndrome. Zika has posed a challenging situation for health, public and economic sectors of affected countries. To quantitate Zika virus neutralizing antibody titers in serum samples, we developed a high throughput plate based Zika virus reporter virus particle (RVP) assay that uses an infective, non-replicating particle encoding Zika virus surface proteins and capsid (CprME) and a reporter gene (Renilla luciferase). This is the first characterization of a Zika virus RVP assay in 384-well format using a Dengue replicon Renilla reporter construct. Serially diluted test sera were incubated with RVPs, followed by incubation with Vero cells. RVPs that have not been neutralized by antibodies in the test sera entered the cells and expressed Renilla luciferase. Quantitative measurements of neutralizing activity were determined using a plate-based assay and commercially available substrate. The principle of limiting the infection to a single round increases the precision of the assay measurements. RVP log_{10}EC_{50} titers correlated closely with titers determined using a plaque reduction neutralization test (PRNT) (R^2>95%). The plate-based Zika virus RVP assay also demonstrated high levels of precision, reproducibility and throughput. The assay employs identical reagents for human, rhesus macaque and mouse serum matrices. Spiking studies indicated that the assay performs equally well in different species, producing comparable titers irrespective of the serum species. The assay is conducted in 384-well plates and can be automated to simultaneously achieve high throughput and high reproducibility.

Introduction

Zika virus (ZIKV), first identified in 1947, is a member of the Flaviviridae [1–3]. ZIKV is closely related to Dengue viruses and is transmitted by Aedes aegypti and Aedes albopictus.
mosquitoes, sexually, and vertically from mother to fetus [2, 3]. ZIKV circulated in Africa, Southeast Asia, and the Pacific regions before it was first detected in South America in 2015 [3]. Major outbreaks in the Americas in 2015, notably in Brazil, linked ZIKV infections with cases of congenital malformations in newborns, Guillain–Barré Syndrome (GBS) and other neurological complications in adults [3, 4]. As there is no specific preventative or treatment for ZIKV infection, there is an urgent medical need for ZIKV vaccines capable of preventing infections, particularly during pregnancy.

Vaccines against other flaviviruses such as Japanese encephalitis virus (JEV), yellow fever virus (YFV), and tickborne encephalitis virus (TBE) elicit neutralizing antibodies directed against the envelope (E) protein in vaccinated subjects and confer protection against disease [5–11]. Published studies support ZIKV neutralizing antibodies as a likely primary immunological endpoint and mechanism of immune-mediated protection from experimental ZIKV challenge [12–16].

The plaque reduction neutralization test (PRNT) or microneutralization test (MNT) approaches have been the gold standards for measuring neutralizing antibody responses against most flaviviruses, including YFV, JEV, and Dengue virus (DENV) [10, 17]. Both the MNT and PRNT performed in 96 well plates are largely manual, labor-intensive assays, which make them challenging and expensive to use in settings such as large clinical trials in which hundreds or thousands of samples need to be tested under good clinical laboratory practice conditions [18, 19]. In addition, both the PRNT and MNT assays rely on the use of infectious virus as a reagent to detect neutralizing antibodies and can have high variability among laboratories depending on the cells used for viral growth, the strain, specific infectivity and maturation state of the virus reagent, and other variations in assay conditions [18, 20, 21].

Reporter virus particles (RVPs) have been used as a substitute for the live virus reagent in neutralization assays to measure antibodies against several flaviviruses including DENV, YFV, JEV, and West Nile Virus (WNV) [22–28], and most recently with ZIKV [16, 28, 29]. RVPs are replication-deficient and deliver their reporter gene to permissive cells [26–28, 30–32]. Flavivirus RVPs containing the virus surface antigens (prM/M and E) have been shown to be antigenically indistinguishable from infectious virus using virus-specific antibodies [26–28, 30–32]. DENV neutralizing monoclonal antibody (mAb) 4G2 neutralized all four serotypes of DENV-RVPs while non-neutralizing mAb 15F3 did not neutralize any [24]. DENV-2 specific neutralizing mAb 3H5 was shown to only neutralize DENV-2 RVP as expected [24]. WNV neutralizing mAb 7H2 also neutralized WNV-RVP [26].

To address some of the limitations of the traditional PRNT and MNT assays, we have developed a ZIKV RVP assay in 384-well plates (Z-RVP-384 assay), that is high throughput, automatable, does not use live ZIKV but rather an RVP that is capable of one round of infection only, and is reproducible. The Z-RVP-384 assay is applicable to measuring serum antibodies in humans and multiple other species. Here we report the development and optimization of the Z-RVP-384 assay and its performance characteristics.

Results
Overview of the Z-RVP-384 assay
The Z-RVP-384 assay detects ZIKV neutralizing antibodies in serum using ZIKV reporter virus particles (Z-RVP) that contain the structural proteins CprME from ZIKV strain SPH2015 and a Renilla luciferase reporter gene in a 384-well plate format. SPH2015 was selected as a representative of circulating ZIKV strains, as RVPs created from five ZIKV strains
representing African (MR-766, ArB7701) and Asian (H/PF/2013, PHL/2012 and THA/2014) have been demonstrated to neutralize ZIKV convalescent serum to equivalent titers [29].

The principle stages of the assay are serum heat inactivation and serial dilution, addition of Z-RVP and neutralization at 37˚C for 1 hour, addition of Vero cells, incubation at 37˚C, 5% CO2, for 72 hours, addition of Renilla substrate and detection of chemiluminescence, and calculation of neutralization titers.

**Assay optimization**

Previously described RVP assays and neutralization assays were used for guidance to determine key assay parameters for assay optimization and control [26–28, 30, 31] with the goal of developing a well-controlled and robust neutralization assay optimized for low assay variability, maximum dynamic range, and potential for high throughput. Critical parameters that were optimized included neutralization duration, RVP concentration, cell concentration, assay incubation time and assay medium.

**Optimization of neutralization duration, cell concentration, assay incubation duration and assay medium.** A design of experiment (DOE; JMP® 13. SAS Institute Inc., Cary, NC, 1989–2019) approach was used to facilitate optimization of Z-RVP-384 assay parameters (neutralization duration, cell concentration, assay incubation time, and assay medium). The goal of the optimization was to minimize assay variability, maximize dynamic range and maximize the signal in relative luciferase units (RLU). The effects of neutralization time (10 min, 35 min, 60 min), Z-RVP reagent per well (2 μL, 4.75 μL, and 7.5 μL), and number of Vero cells per well (1500, 5750, 10000) were investigated. Heat-inactivated ZIKV hyperimmune rabbit serum was diluted 1:5 in assay media then serially diluted 5-fold ten times. The experiment was then conducted according to 16 experimental combinations determined using a custom JMP 13 DOE method as described by JMP13 [33]. The DOE was then analyzed based on the EC50 titers and confidence limits, V-factor and dynamic range. The V-factor gives a realistic measure of the overall assay performance by accounting for intermediate points in the dose-response curve that have higher variability due to effects of computation and dispensing errors [34]. V-factor is calculated by using the formula

\[ V\text{-Factor} = 1 - \frac{6 \cdot \text{mean} (\sigma_p - \sigma_n)}{\sigma_p} \]

where \( \sigma \) is standard deviation (SD) of the curve and \( \sigma_p \) is the SD for positive control and \( \sigma_n \) is SD for negative control [35]. A 4-parameter non-linear regression model was used to obtain the EC50 titers and confidence limits. The dynamic range was calculated using the formula: Dynamic range = Average Max RLU signal – Average Min RLU signal. The DOE stepwise modeling demonstrated that the Z-RVP amount per/well and the cells/well significantly impacted the assay. The next step was to set the “desirability” for each parameter to be optimized. The desirability is set by determining the goal of each response such as maximizing the dynamic range and V-Factor, minimizing the confidence limits and setting the “importance” to predict the neutralization time, Z-RVP amount and optimal number of Vero cells as shown in prediction profiler (Fig 1).

The prediction profiler determined the parameters which resulted in the lowest confidence limits and the highest V-factor and dynamic range as RVP/well: 5.2, cells/well: 4625 and neutralization time: 60 minutes. Optimized parameters were repeated in a confirmatory assay run. Next, we compared assay duration of 48 hours, and 72 hours. A 72 hour assay duration resulted in higher RLU of 397,000 as compared to a RLU of 331,000 after 48 hr. Optimized assay parameters were defined as neutralization for 60 min at 37˚C, using 5.25 μL RVP of lot 164C (optimal RVP amount is reassessed for each lot), and 4625 Vero cells/384-well with an assay duration of 72 hours.

**Z-RVP reagent assessment.** The structure, antigenicity, stability and reproducibility of the Z-RVP reagent has been described [32]. The Z-RVP reagent was assessed for relative
infectivity and cytotoxicity. The Z-RVP reagent was supplied as single-use aliquots and stored frozen at < -60˚C. Immediately prior to use Z-RVP aliquots were rapidly thawed in a 37˚C water-bath and kept on ice until use.

Akin to virus preparations, each lot of RVP has a different level of infectivity and therefore a standard infectivity assay was carried out to establish the input concentration of a specific lot of Z-RVP. Relative Z-RVP infectivity was assessed by titration from 7.5 μL to 0.5 μL per 384-well using serial dilution in assay medium alone. Neat or diluted Z-RVP (7.5 μL) was transferred to a 384-well plate and Vero cells in assay media added to a final volume of 22.5 μL/well. Plates were incubated in a humidified incubator at 37 ± 2˚C and 5% (±1%) CO₂ for 72 ± 2hrs and read using the Renilla-Glo Luciferase Assay System. Only Z-RVP lots that

Fig 1. Predicted optimal combination of factors with maximal desirability. DOE analysis was carried out using the optimization and desirability settings (minimized with the relative importance set to 1. V-factor: maximized with the relative importance set to 0.7. Dynamic Range: maximized with the relative importance set to 1) in JMP13. The curves show the predicted interaction between the different factors. Flat lines indicates no predicted interaction. The horizontal redlines show the predicted optimal parameter and the vertical red lines show the geometric mean of the desirability measured.

https://doi.org/10.1371/journal.pone.0250516.g001
resulted RLU > 100,000 were used in subsequent experiments to ensure adequate dynamic range between full neutralization (no signal) and no neutralization (maximum signal).

Potential cell toxicity of the Z-RVP reagent lot 229A on Vero cells plated at 4625 cells/well was assessed using the CellTiter-Glo detection System in parallel to the Z-RVP infectivity. The results of the CellTiter-Glo study demonstrate that Vero cells are viable at the optimal concentration of cells determined by the DOE (Fig 2). The RLU signal increased with increasing amount of Z-RVP. No toxicity of the Z-RVP reagent on cells was observed with the 16 lots of Z-RVP tested. Of these lots, 8 were selected for use in assay development.

**Determination of optimal Z-RVP particle input.** As the read-out of the Z-RVP-384 assay was chemiluminescence signal, the Z-RVP reagent was optimized towards both achieving a minimum required signal as well as observing the law of mass action: Antibodies in undiluted serum are to greatly outnumber Z-RVP particles to assure that binding of antibodies to the antigen do not change the dynamics of neutralization [31]. We established a minimum chemiluminescence signal of 100,000 RLU to allow for adequate range across the neutralization curves, with a maximum signal predetermined by the chemiluminescence reader capacity of 1x10^7 RLU.

To determine the optimal Z-RVP input per well for the lot 229A Z-RVP lot was titrated from 0.5 μL to 7.5 μL in a neutralization assay using positive control antisera (three different rabbit sera, generated by immunizing with purified live ZIKV, strain PRVABC59 (Serum 1) or Dakar (Sera 2 and 3)). Neutralization curves were generated for the different Z-RVP dilutions as show in Fig 3. The log_{10}EC_{50} titers for the three sera were then examined against input Z-RVP amount to determine a stable (similar) titer that was consistent with the titers produced using other Z-RVP lots. Z-RVP lot 229A input amounts of 2 μL and 3 μL resulted in similar log_{10}EC_{50} values within the variation of the assay (0.2log_{10}) for all three positive control sera (Table 1). The midpoint of 2.5 μL was chosen as optimal for this Z-RVP lot and assay conditions.
Determination of area of stable log�EC50 titers for three sera positive for ZIKV neutralizing antibodies using different input amounts of Z-RVP reagent (lot 229A). Z-RVP lot 229A input amounts of 2 μL and 3 μL resulted in similar log�EC50 values within the variation of the assay (0.2log10) for all three positive control sera.

**Signal stability, replication of measurements, and plate layout.** The stability of the Renilla RLU signal in 384-well plates was assessed through an interleaved assay to determine uniformity and separation of signals to determine edge effect, drift or other spatial effects present in the assay as outlined in the Assay Guidance Manual by Eli Lilly & Company and the National Center for Advancing Translational Sciences [35]. The same operator carried out duplicate tests on two separate days (day 1, day 2) of maximum (max), mid, and minimum (min) RLU generating serum samples in different positions. The maximum RLU serum sample was generated by diluting negative rabbit serum in assay media at a 1:1607.5 dilution. The mid RLU serum sample was generated by diluting ZIKV positive rabbit serum against ZIKV strain PRVABC59 in assay media at a 1:1607.5 dilution. The minimum RLU serum sample was generated by diluting the ZIKV positive rabbit serum against ZIKV strain PRVABC59 in assay media at a 1:5 dilution. For each max, medium and min RLU on the plate the mean RLU, standard deviation (SD) and Coefficient of Variation (CV) were determined. The % RLU midpoint as a surrogate EC50 between the three serum dilutions was calculated by the following equation: 

\[
\% \text{RLU midpoint} = \frac{\text{AVG (mid) \times 100}}{\text{AVG (max) - AVG (min)}}
\]

AVG (min) was the average taken over the three minimum signal plate averages, and AVG (max) was the average taken over the three maximum signal plate averages [35]. The % RLU midpoint assessed the stability of the RLU midpoint while allowing for variation between max and min RLUs between plates. Acceptance criteria were based on the recommendations specific to high throughput screening assay validation in the Assay Guidance Manual by Eli Lilly & Company and the National Center for Advancing Translational Sciences [35]. The following acceptance criteria were established: CV (of the mean) ≤ 20%, SD midpoint < 20%, RLU (signal) window ≥ 2, Z’ factor ≥ 0.4, drift or edge effects < 20%.

**Table 1. Titration of Z-RVP reagent for use in the Z-RVP-384 assay.**

| RVP lot 229A input (μL) | Average RLU | Serum 1 Log�EC50 | Serum 2 Log�EC50 | Serum 3 Log�EC50 |
|------------------------|-------------|-----------------|-----------------|-----------------|
| 7.5                    | 1,037,777   | 3.89            | 4.65            | 4.36            |
| 5.25                   | 857,748     | 4.06            | 4.68            | 4.37            |
| 4                      | 796,357     | 4.14            | 4.62            | 4.48            |
| 3                      | 644,667     | 4.06            | 4.94            | 4.83            |
| 2                      | 408,427     | 4.17            | 4.90            | 4.96            |
| 1                      | 217,585     | 4.68            | 5.12            | 4.96            |
| 0.5                    | 146,924     | 5.38            | 5.31            | 5.75            |

https://doi.org/10.1371/journal.pone.0250516.t001
The % midpoint RLU activity was consistent between occasions with a less than 2-fold difference in midpoint between plates (between plates; between occasions). The acceptance criteria for inter-plate and inter-day tests were met. The mean CV of the RLU signal by sample, plate, and day was assessed. A significant edge effect of rows A and P was identified, and these rows were subsequently excluded from use and filled with assay media. Similarly, the edge columns 1 and 24 were excluded from use leaving the central plate area containing 308 wells (14 rows and 22 columns). A plate layout was established: 12 test samples, 2 controls (1 negative serum, 1 positive serum) each titrated in eleven 3-fold serial dilution steps to accurately determine neutralizing antibody EC\textsubscript{50} from an EC\textsubscript{50} titer of 32 (1:8 initial serum dilution x2 for Z-RVP addition x2 for cell addition) to and EC\textsubscript{50} titer of 100,000 (upper limit of detection).

Above an EC\textsubscript{50} titer of 100,000 (or 5.0 log\textsubscript{10}), a lack of upper asymptote data points led to an increase in variability in the EC\textsubscript{50} titer. Testing of sera with a potency > 5.0 log\textsubscript{10} required an additional predilution step of the serum (e.g. start the serum input at 1:200 rather than 1:8).

Z-RVP-384 assay performance

Several assay parameters were examined to determine the reliability of the assay in determining ZIKV neutralizing antibody titers in sera from human, rhesus macaque, and mouse using the principles and recommendations of the ICH Quality guidelines Q2 Analytical Validation [36]. We determined dilutional linearity, limits of detection and quantitation, repeatability, intermediate precision, and specificity.

**Dilutional linearity and identification of serum matrix effect.** The linearity of an assay is the capability to generate results directly proportional to the expected quantity of analyte in the sample. ICH recommends in its guidelines that the linearity of the assay is evaluated across its range with a minimum of five concentrations tested [36].

Dilutional linearity in assay media was evaluated on four occasions using a rabbit ZIKV hyperimmune serum. The serum was diluted in a series of two-fold steps in assay media (1:32 to 1:4096). Each serum dilution was titered six separate times on 4 occasions, generating 24 measurements per dilution resulting in average log\textsubscript{10} EC\textsubscript{50} neutralizing antibody titers that ranged from 1.54 to 4.26. The assay was linear in assay media over the range tested with $R^2 = 0.968$, root mean square error (RMSE) = 0.13 log\textsubscript{10} (Fig 4). The assay media dilutional linearity was subsequently used to determine the ULOQ.

Following dilutional linearity assessment in assay media, a linearity study was utilized to define the matrix effect of the assay in human and cynomolgus macaque serum naïve serum. Two ZIKV antibody positive cynomolgus macaque sera and two ZIKV antibody positive human sera were serially diluted in two-fold steps in negative human serum or cynomolgus macaque serum respectively. Each diluted serum sample was analyzed for log\textsubscript{10}EC\textsubscript{50} 8 or 16 times (human, cynomolgus macaque samples, respectively) and plotted against the dilution factors (Fig 5).

The assay was linear and accurate in human serum over a serum dilution range resulting in neutralizing titers between ~3.5 log\textsubscript{10}EC\textsubscript{50} to ~2 log\textsubscript{10}EC\textsubscript{50} (Fig 5A) and ~3 log\textsubscript{10}EC\textsubscript{50} to ~2 log\textsubscript{10}EC\textsubscript{50} (Fig 5B, Table 2). In cynomolgus macaque serum the linear dilution range resulted in neutralization titers of ~3 log\textsubscript{10}EC\textsubscript{50} to ~2.3 log\textsubscript{10}EC\textsubscript{50} (Fig 5C) and ~2.8 log\textsubscript{10}EC\textsubscript{50} to ~2.3 log\textsubscript{10}EC\textsubscript{50} (Fig 5D, Table 2). The observed neutralization titers determined by serial dilution in serum are summarized as the geometric mean $\sqrt[n]{\prod_{i=1}^{n} x_i}$ of the EC\textsubscript{50} for each dilution series and compared to expected neutralization titers [37] (Table 2). The expected neutralization titers were calculated using the first determined EC\textsubscript{50} titer (geometric mean) as reference and dividing by 2 for each 2-fold dilution step (Table 2). A matrix effect was observed for both
cynomolgus macaque sera as an increase of observed geometric mean EC\textsubscript{50} over expected EC\textsubscript{50} greater than 200% and thereby exceeding expected assay variation of up to two fold. A matrix effect was observed for human serum sample 2 due to a lower starting titer. These results indicated a serum matrix effect, defined as a titer resulting not from ZIKV-neutralizing antibodies but from nonspecific ZIKV inhibitory activity in serum. These detected levels of matrix effect in the four dilution series (Fig 5, Table 2) were the result of the matrix effects of the individual sera (presumed negative) used for the dilution series. Therefore, a serum matrix effect was demonstrated using sera of animals and humans unexposed to flaviviruses.

Next, we investigated the matrix effect of serum from CD-1 mice and Indian rhesus macaques [38]. Typical regression curves of negative sera which indicate a matrix effect only and of positive sera are shown in Fig 6A and 6B. The ZIKV positive sera were collected from humans, rhesus macaques and CD-1 mice post-immunization with an experimental purified inactivated Zika vaccine (PIZV). In some instances, an EC\textsubscript{50} values could not be calculated for negative sera using nonlinear regression curves. Once the nonlinear regression curve’s lower asymptote was constrained to 0 the log\textsubscript{10} EC\textsubscript{50} titers for negative sera could be calculated while positive sera were unaffected (Fig 6C).

To comprehensively evaluate the matrix effect of the serum in the Z-RVP-384 assay, we tested flavivirus-negative sera from human, rhesus macaques, and CD-1 mice. Negativity was
determined by lack of flavivirus-binding antibody (a broadly cross reactive flavivirus IgG detection assay) for human and rhesus macaque sera; mouse sera were assumed to be negative. Sera from 124 flavivirus antibody negative humans, 84 rhesus macaques, and 69 CD-1 mice were tested. The upper 95% quantile of the population distribution of negative sera was used to define the threshold between negative sera (showing matrix effect) and positive sera. The 95% quantile for negative human serum was found to be 2.02 log_{10} EC_{50}, for negative rhesus macaque serum 2.12 log_{10} EC_{50}, and for CD-1 mouse serum 2.18 log_{10} EC_{50} (Fig 7 and Table 3).

Fig 5. Dilutional linearity of the Z-RVP-384 assay in serum matrix. (A, B) Two positive human sera were diluted in negative human serum. (C, D) Two positive cynomolgus macaque sera were diluted in negative cynomolgus macaque serum. Serial dilutions test stocks were generated and titrated 8–16 times.

https://doi.org/10.1371/journal.pone.0250516.g005
We assessed whether the small difference between the thresholds for mouse, rhesus macaque and human sera were significant using One-Way ANOVA of means with Tukey’s Honest Difference multiple comparison. The matrix effect of CD-1 mouse serum was significantly higher than both human and rhesus macaque sera (p < 0.0001 for both) and the matrix effect of rhesus macaque serum was higher than that of human serum (P = 0.0002).

Repeatability and intermediate precision. Assay precision is a measure of the closeness of repeated measurements and can be assessed as repeatability (repeat measurements of a sample at the same occasion with one operator) and intermediate precision (repeat measurements of a sample on several occasions by several operators) [36]. Following ICH guidelines, the robustness of the Z-RVP-384 assay was assessed using the dataset of dilutional linearity in assay media with JMP13 (SAS, USA). The precision was determined by fitting a mixed effects model to the data.

### Table 2. Matrix effect observed in human serum and cynomolgus macaque serum.

| Dilution | Human serum 1 | Human serum 2 |
|----------|---------------|---------------|
|          | 2 4 8 16 32 64 | 2 4 8 16 32 64 |
| observed EC<sub>50</sub> | 4132 1883 899 452 203 110 | 882 509 260 186 101 67 |
| expected EC<sub>50</sub> | reference 2066 1033 516 258 129 | reference 441 221 110 55 28 |
| observed % of expected | 100 91 87 88 79 85 | 100 115 118 169 182 242 |

| Cynomolgus macaque serum 1 | Cynomolgus macaque serum 2 |
|-----------------|-----------------|
| Dilution | 2 4 8 16 32 64 | 2 4 8 16 32 64 |
| observed geomean EC<sub>50</sub> | 834 484 265 201 175 163 | 513 326 239 204 161 140 |
| observed % of expected | 100 116 127 193 336 626 | 100 127 186 318 503 871 |

Final dilutions in serum are shown. Observed % of expected was calculated by observed geomean EC<sub>50</sub>/ expected EC<sub>50</sub> *100%.

https://doi.org/10.1371/journal.pone.0250516.t002

Fig 6. Typical Z-RVP-384 assay neutralization curves of three species using negative and positive sera. Nonlinear regression neutralization curves of human, rhesus macaque, and mouse serum from vaccinated subjects (+ PIZV) or nonvaccinated subjects (Matrix; defined as naïve serum of the species). Each serum dilution was measured in duplicate and the lower asymptote of the nonlinear regression curve was constrained to 0 (A) or left unconstrained (B). Neutralization Titers in log<sub>10</sub> are shown in (C) as calculated by nonlinear regression in GraphPad Prism. Cannot calculate = effect on curve was too low to calculate a titer.

https://doi.org/10.1371/journal.pone.0250516.g006
model to the data, with the dilution being a fixed effect and operator, day, and plate being random effects. From this analysis, the intermediate precision of the assay was determined to be 0.14 log10 (Table 4), corresponding to 1.38 fold variability and 38% GCV (geometric coefficient of variation) with manual pipetting. The greatest contributor to assay variance was Day (occasion) confounded by operator, accounting for 57% of the total variance observed (Table 4). A factor contributing to this variance may be differences in Vero cell preparation on a day to day basis (Table 4). Assay repeatability was described by the term ‘within’ and had a SD of 0.08 log10EC50.

Fig 7. Matrix effect on the Z-RVP-384 assay by species. Quantile plots of log10EC50 values are shown for 124 human, 84 rhesus macaque, and 69 CD-1 mouse sera. Titers below 1.5 log10 are extrapolated (only included for demonstration), and should be reported as < LOD/LLOQ.

Table 3. Positive serum cut-off for the Z-RVP-384 assay in human, rhesus macaque and mouse serum.

| Species of serum | Sample test number | 95% quantile (log10EC50) |
|------------------|-------------------|-------------------------|
| Human            | 241*              | 2.02                    |
| Rhesus macaque   | 84                | 2.12                    |
| CD-1 mouse       | 69                | 2.18                    |

* includes replicate titration of clinical trial samples.
Limits of quantification. Limits of quantification are characterized by the upper and lower limits that are both accurate and precise. To estimate the upper limit of quantitation (ULOQ) of the Z-RVP-384 assay, a high titer rabbit hyperimmune serum (estimated titer of ~5 \( \log_{10} \text{EC}_{50} \)) was pre-diluted 1:8, 1:25, 1:50, 1:200 and 1:400 in assay medium and titered in separate experiments (Fig 8A) the standard error and % Fit Error (FE) was stable from the 1:25–1:200 dilutions (Fig 8B). The upper limit of quantitation (ULOQ) of the Z-RVP-384 assay was dependent on determination of the upper asymptote of the non-linear regression curve (no neutralization, maximum RLU). For highly potent sera few, if any, measurements are made at the upper asymptote, increasing variability in the curve fit and of the \( \text{EC}_{50} \) determination. No higher potency serum was available for further determination of the ULOQ. A preliminary upper limit of quantitation (ULOQ) for the assay was set at 5.00 \( \log_{10} \text{EC}_{50} \) with higher titers requiring retesting of the sample at a pre-dilution of 1:200 in assay media.

To identify the lower limit of quantitation, the precision analysis from the assay media dilution linearity study and the observed matrix effect were evaluated. The assay was precise to the 1:32 dilution. However, in serum matrix the assay was shown to be linear and accurate down to the matrix effect as described previously.

The Z-RVP-384 assay demonstrated linearity and precision in assay media (Fig 4) beyond the determined serum matrix effect. The matrix effect serves as the LLOQ. Analyte sensitivity

---

**Table 4. Variance components of assay robustness assessment.**

| Component                | Variance component | %    | SD  |
|--------------------------|--------------------|------|-----|
| Operator                 | 0.000              | 0    | 0.00|
| Day [Operator]           | 0.011              | 57   | 0.11|
| Plate [Operator, Day]    | 0.002              | 10   | 0.04|
| Within                   | 0.007              | 33   | 0.08|
| Total                    | 0.0200             | 100  | 0.14|

* Standard deviation (SD) calculated as the square root of the variance component

**Fig 8. Determination of the ULOQ of Z-RVP-384 assay.** (A) Neutralization curves of several dilutions of high potency rabbit serum in assay media to estimate the ULOQ for the standard assay. A rabbit hyperimmune serum generated by immunization with live ZIKV (Dakar) was diluted in assay media 1:8, 1:25, 1:50, 1:200, and 1:400. (B) \( \log_{10} \text{EC}_{50} \) titers generated by each serum dilution shown with Standard error (SE) of the \( \log_{10} \text{EC}_{50} \) estimate and % FE (SE \* LN(10) / 100).

https://doi.org/10.1371/journal.pone.0250516.g008
is defined by the LLOQ, as such the sensitivity of the assay is restricted to analyte values at or above the evaluated matrix effect. The standard assay range was defined as the interval between LLOQ and ULOQ [36] and resulted in: 105 to 100,000 EC$_{50}$ (human sera), 132 to 100,000 EC$_{50}$ (rhesus macaque sera), and 151 to 100,000 EC$_{50}$ (mouse sera). For sera with potency greater than a 100,000 EC$_{50}$, a predilution can be included for the serum to meet sample acceptance criteria.

**Neutralizing antibody titers are not affected by species.** Having demonstrated a serum matrix effect of the Z-RVP-384 assay in three species (Fig 7), we investigated whether ZIKV neutralizing antibodies would be measured equivalently by the Z-RVP-384 assay between all three matrices. Negative human, rhesus macaque, and mouse sera were spiked with either monoclonal antibody (mAb) 2C8 or mAb ZKA64, both of which neutralize ZIKV, at a starting mAb concentration of 1 μg/mL. A ZIKV neutralizing rhesus macaque polyclonal serum was also diluted into each negative serum matrix at 1:20. Non-neutralizing mAb 4G2 and negative serum were spiked into the sera as controls. Neutralization titers were determined for each spiked sample eight times (Fig 9A–9C). The absolute neutralization titer values obtained for human, rhesus macaque, or mouse sera spiked with mAb 2C8 or ZKA64 were consistent with previously published observations [39, 40]. No significant differences in neutralization titers were detected among the different serum matrices spiked with mAbs by One-Way ANOVA of means (Fig 9A and 9B). Neutralization titers of sera spiked with the rhesus macaque polyclonal serum were also consistent across the three species with no significant differences detected by one-way ANOVA of means (Fig 9C). A Grubbs test (alpha = 0.05) conducted in GraphPad PRISM identified the result from one mouse serum spiked with macaque serum as an outlier, but inclusion or exclusion of this outlier did not affect the result of the statistical analysis. The differences between neutralization titers of each matrix/spiking group were plotted with 95% CI (Fig 9D). The differences in mean neutralization titers, including all 95% CI fell within the assay variation of 0.2 log$_{10}$ (Fig 9D).

**Specificity of the Z-RVP-384 assay.** Assay specificity is the ability of an assay to assess the analyte in the expected matrix [36]. To determine the specificity of the Z-RVP-384 assay for ZIKV neutralizing antibodies, we tested sera from rhesus macaques vaccinated with ZIKV vaccine candidate PIZV (Takeda, Japan), YFV vaccine (STAMARIL®, Sanofi, France), JEV vaccine (IXIARO®, Valneva, Austria), WNV vaccine (West Nile -Innovator®, Fort Dodge Animal Health, USA), or TBE vaccine (ENCEPUR®, GSK, Switzerland). PIZV elicited high neutralizing antibody titers 30 days and 90 days after two immunizations. Other than ZIKV vaccine (PIZV), two of four tested flavivirus vaccines elicited low-level cross-reactive neutralizing antibodies in the Z-RVP-384 assay 30 days after boost vaccination, which dropped to serum background levels by 90 days after second immunization (Table 5). These data demonstrate specificity of the Z-RVP-384 assay for neutralizing antibodies elicited by the candidate ZIKV vaccine when compared to YFV, JEV, WNV, and TBE vaccines.

**Correlation of Z-RVP-384 and PRNT assay**

We performed a correlation analysis of the Z-RVP-384 assay with a ZIKV PRNT assay (Q2 Solutions, San Juan Capistrano, CA). The comparison used serum titer results from over 120 subjects collected after first (day 29) and second PIZV vaccinations (day 57) from clinical trial ZIK-101 (ClinicalTrials.gov identifier: NCT03343626) [41]. For correlation analysis, Z-RVP-384 titers and PRNT titers below their respective lower limits of quantitation (LLOQ) were replaced with half of the LLOQ value. Correlation of results between the two assays was highly significant with a Spearman correlation coefficient of 0.94 (Fig 10). This suggests that the Z-RVP-384 and PRNT assays are measuring the same or similar antibody-virus interactions.
Fig 9. The Z-RVP-384 assay consistently measure neutralizing titers in human, rhesus macaque and CD-1 mouse sera. ZIKV neutralizing titers in human, rhesus macaques (NHP) and mouse sera was measured after addition of (A) mAb 2C8; (B) mAb ZKA64; (C) ZIKV neutralizing rhesus macaque polyclonal serum. (D) differences in mean log_{10}EC_{50} titers plus 95% CI between the different sera, by spiking group. For mAbs EC_{50} are expressed as ng/mL, and for sera EC_{50} are expressed as reciprocal serum dilution.

https://doi.org/10.1371/journal.pone.0250516.g009
Performance of the international ZIKV antibody standard in the Z-RVP-384 assay

Assay accuracy compares the value determined by an assay to an accepted value such as that assigned to a reference standard [36]. No reference standard for ZIKV neutralizing antibodies is available. However, an international serum standard (16/352) for ZIKV antibodies has been developed by WHO and NIBSC which has been assigned an international unit value (250 IU/ampoule) [42]. A prototype of the Z-RVP-384 assay was used in the evaluation of this standard [42]. We retested the international serum standard (16/352) in the updated Z-RVP-384 assay.

NIBSC standard 16/352 was reconstituted and aliquoted into single use aliquots for testing by 4 different operators on 9 separate occasions in the manual Z-RVP-384 assay. By Z-RVP-384 the standard 16/352 had an average titer of 4.24 log\textsubscript{10} EC\textsubscript{50} and Standard Deviation of 0.2 log\textsubscript{10} EC\textsubscript{50}.

Automation of serum preparation

An important element of ZIKV neutralizing antibody assay development was capability for high throughput to enable rapid testing of large numbers of clinical samples. A proof of concept assessment of Z-RVP-384 assay automation was conducted to determine feasibility of a high throughput operation. As an initial step, serum serial dilution was automated using a Tecan 780 Fluent liquid handler using a 384-tip head (Tecan, Switzerland). Two positive controls, one negative control and 11 serum samples ranging in ZIKV neutralization titers from negative to high positive were run once per plate on 6 plates per occasion (day) and on 4 separate occasions to generate a total of 24 measurements per sample. The location of the samples on each plate was varied among the 6 plates to maximize assay variation. In total 336 measurements were performed.

Five samples failed the sample acceptance criteria, a 1.49% failure rate. Using automation, the assay GCV of the log\textsubscript{10} EC\textsubscript{50} titers was 22%, compared with 38% GCV of the manual Z-RVP-384 assay and time for the serum dilution step was reduced by 50%.

Discussion

ZIKV caused a significant epidemic in South America, Central America, and the Caribbean during 2015–2016 with 1 million cases, resulting in the declaration of a Public Health Emergency of International Concern by WHO [43, 44]. As response to this outbreak, multiple efforts have been initiated to develop a safe and effective vaccine with several candidates

| Flavivirus/Vaccine name | Mean Log\textsubscript{10}EC\textsubscript{50} titer\textsuperscript{1} | Mean Log\textsubscript{10}EC\textsubscript{50} titer\textsuperscript{2} |
|-------------------------|---------------------------------|---------------------------------|
| ZIKV vaccine (PIZV\textsuperscript{2}) | 4.62 (SD: 0.14) | 4.10 (SD: 0.06) |
| YFV/STAMARIL\textsuperscript{R} | <LLOQ | <LLOQ |
| JEV/IXIARO\textsuperscript{R} | 2.13 (SD: 0.11) | <LLOQ |
| WNV/West Nile-Innovator\textsuperscript{R} | 2.20 (SD: 0.30) | <LLOQ |
| TBE/ENCEPUR\textsuperscript{R} | <LLOQ | <LLOQ |

\textsuperscript{1} Mean titers of sera from 4 macaques per flavivirus vaccine group
\textsuperscript{2} Candidate ZIKV vaccine
LLOQ of the assay is 2.12 Log\textsubscript{10}EC\textsubscript{50}

https://doi.org/10.1371/journal.pone.0250516.t005
currently in clinical development [45, 46]. Neutralizing antibodies against ZIKV have been proposed as an important immune marker for clinical benefit [12, 14–16, 47]. Several assays have been developed to measure the level of ZIKV neutralizing antibodies in serum. The traditional flavivirus neutralization assays, the PRNT and MNT assays, are low throughput, imprecise, manual labor intensive and represents a major bottleneck in testing large numbers of sera for clinical studies [18, 19, 21]. To address some of the limitations of the traditional PRNT and MNT assays, we have developed a reproducible, high throughput, automatable 384-well plate ZIKV RVP assay for measuring serum antibodies in humans, rhesus macaques and mice, and that eliminates use of infectious ZIKV.

Immunogenicity, efficacy and safety in nonclinical models is an important aspect of development of ZIKV vaccine candidates [48, 49] as the current low prevalence of ZIKV infections make Phase III efficacy studies difficult to conduct. To facilitate comparison, and potentially

Fig 10. Correlation of ZIKV neutralization titers in human sera using Z-PRNT and Z-RVP-384 assays. Human sera from a clinical trial of PIZV (ZIK-101) day 29 (post dose one sera) and day 57 (post dose two sera) were tested in both Z-PRNT (Y axis) and Z-RVP-384 (X-axis) and log_{10}-transformed titers plotted. A Spearman correlation analysis was conducted in R and showed a strong correlation of 0.94.

https://doi.org/10.1371/journal.pone.0250516.g010
bridging of immunogenicity data from animal models to humans, the ideal assay would use the same reagents regardless of species, and titer measurement should be unaffected by serum matrix from the different species [48–50]. We detected a matrix effect in unvaccinated (naïve) animals and humans with our Z-RVP-384 assay and used a population approach to set a cutoff value between naïve sera and sera containing ZIKV neutralizing antibodies. As demonstrated by spiking experiments, the serum matrix from the different species did not affect RVP titers above the cutoff value indicating that the Z-RVP-384 assay can be used to compare neutralizing antibody titers across different species. A low level of flavivirus cross-reactive antibodies could be detected in the Z-RVP-384 assay. The effect of prior flavivirus exposure on ZIKV infection or ZIKV vaccination is not well understood and therefore further studies are required. The development of a ZIKV specific neutralizing antibody assay to evaluate ZIKV vaccine efficacy and to determine a surrogate endpoint that predicts clinical benefit would be of great value in a flavivirus endemic area.

We observed a strong correlation between neutralizing titers from the Z-RVP-384 assay and the PRNT assay, suggesting that the two assays are measuring the same antibody-virus interaction including blocking cell entry. Others have also explored other assays for measuring ZIKV neutralizing antibodies such as RVP (WNV-based replicon) neutralization assay, using a flow cytometer and a GFP readout [29], RVP (WNV-based replicon)-based microneutralization assay, using a 96-well format and a GFP readout [28], RVP (DENV-based replicon) based microneutralization assay using a 96-well format and chemiluminescence readout [16]. Multiple parameters of flavivirus neutralizing antibody assays vary among labs, complicating study comparisons. The use of international standards, such as the WHO/NIBSC standard 16/352 [42] could be of great value to compare absolute titer results determined by different assays, on different sample sets, and by different laboratories.

Conclusions

We have developed a safe, robust and automatable ZIKV RVP neutralization assay that reproducibly measures neutralizing antibody titers in sera from multiple species, correlates with a qualified ZIKV PRNT assay, relies on commercially available reagents and is suitable for validation according to 21 CFR part 11. This Z-RVP-384 assay lends itself to the reliable assessment of large sample sets for clinical trials.

Material and methods

Ethics statement

The sera used for Z-RVP-384 assay development were obtained from animal studies that were approved and conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Research Council. Details of the studies are described in the S1 File.

CD-1 mouse study. All in-life practices, including husbandry and environmental enrichment, were approved and conducted per Institutional Animal Care and Use Committee (IACUC) of Millennium Pharmaceuticals, Inc. Cambridge, MA USA under protocol #16-06-175. Euthanasia (carbon dioxide asphyxiation) was performed in accordance with accepted America Veterinary Medical Association (AVMA) guideline.

Rabbit study. All in-life practices, including husbandry and environmental enrichment, were approved and conducted per IACUC of Covance under protocol 0141–16. Rabbits were monitored for signs of morbidity and/or mortality daily according to animal welfare act and AAALAC. Rabbits were given Ketamine and Xylazine (anesthesia and analgesia) before euthanization by CO2 inhalation and exsanguination.
**Primed rhesus macaque study.** All in-life practices, including husbandry and environmental enrichment, were approved and conducted per IACUC of Inotiv under protocol #2384–14376. Macaques were monitored at least twice daily for stress or suffering, and body weight was measured on D1 prior to dosing and monthly thereafter. Cageside observations included observation for mortality, moribundity, general health, and signs of toxicity. Treatment with the vaccines had no effect on mortality, physical examinations, cageside observations, body weights or body weight changes. Moribund animals and all surviving animals at the end of the study were euthanized by intravenous injection of sodium pentobarbital (or equivalent) and exsanguinated.

**Flavivirus Naïve rhesus macaque study.** Rhesus macaque sera were obtained from a previously published PIZV vaccination and ZIKV challenge study [51] conducted at Charles River Laboratories (CRL), Mattawan, MI. All in-life practices, including husbandry and environmental enrichment, were approved and conducted per IACUC of CRL under protocols #2715–001 and #2715–002.

**Cynomolgus macaque study.** Cynomolgus macaque sera were obtained from a previously published ZIKV challenge study conducted at Wisconsin National Primate Research Center [52]. Madison, WI USA. All in-life practices, including husbandry and environmental enrichment, were approved and conducted per IACUC of The University of Wisconsin-Madison, College of Letters and Science and Vice Chancellor for Research and Graduate Education Centers Institutional Animal Care and Use Committee under protocol number G005401-R01.

**ZIKV reporter virus particle (Z-RVP) reagent**

Reporter virus particles (RVP) were purchased from Integral Molecular (Philadelphia, PA). ZIKV reporter virus particles (Z-RVPs) contain CprM/E from ZIKV strain SPH2015 packaged within the particle a DENV-based replicon with the Renilla luciferase gene [32]. The Z-RVP reagent is replication deficient but is capable of infecting permissive cells to deliver the replicon which drives the expression of Renilla luciferase. Addition of an appropriate substrate results in the generation of a chemiluminescent signal, which is measured to determine sample neutralization activity. The SPH2015 strain of ZIKV was the first strain isolated from the outbreak in Brazil in 2015 and has a high degree of genetic similarity to other ZIKV strains from the same outbreak in South and Central America during 2015–16 and other recent Asian-lineage ZIKV strains [53].

Eight RVP lots were used during the development of the assay (lot 135 A-D, 164 A-D). Each lot number represents a different production run, each letter of the lot represents a different harvest date.

**Assay media**

Opti-MEM no phenol red (Gibco, 11058–021) supplemented with 10% Fetal Bovine Serum, heat-inactivated (Sigma, F4135-100ML, lot 17L179) and 1% Penicillin/Streptomycin (Gibco, 15140–122).

**Vero cells**

Vero cells were obtained from ATCC (CCL–81.4) and expanded into a research cell bank (non-CGMP). The cell bank was confirmed to be mycoplasma negative. Cells were maintained in DMEM Growth media (Corning, 15017CV) plus 10% FBS, (Sigma, F4135–100ML, 17L179), 2mM L-Glutamine (Gibco, 25030–054) in 5% CO₂, at 37 ± 2˚C using tissue culture flasks (Corning, 10-126-061). Vero cells were split with 0.05% EDTA-Trypsin (Gibco, 25300).
Sera and monoclonal antibodies

All sera were heat-inactivated at 56°C for 30 min. Positive serum was defined as serum that contained ZIKV-neutralizing antibodies tested using a CPE based microneutralization assay. Negative serum was defined as serum that had no neutralizing activity against ZIKV above the species-specific matrix effect. The negative serum used throughout assay development and carried forward as assay acceptance control was negative rabbit serum (IGMS-SER, Innovative Research, USA). The positive serum used throughout assay development was generated by Takeda by immunizing rabbits with live ZIKV preparation using strain Dakar41524 and strain PRVABC59 (anti-Dakar L777P16, anti-Dakar L821P119, anti-PRVABC59 L773P08). These positive sera were used to optimize the assay and as acceptance controls. Test sera to establish species specific matrix cut-offs came from mouse (CD-1 strain), from rhesus macaques, and from humans (clinical trial ZIK101, clinicaltrial.gov identifier: NCT03343626). The rhesus macaque sera and human sera were determined to be negative for flavivirus-binding antibodies by flavivirus-screening luminex assay (Luminex® Corp (Austin, TX, USA) and Ampersand Biosciences (Lake Clear, NY, USA).

Two monoclonal antibodies (mAb) were used in the assessment of the Z-RVP-384 assay: ZKA64 is a neutralizing mAb that has been reported to be ZIKV specific [40]. 2C8 is an EDE domain antibody that neutralizes both DENV (serotype 1–4) and ZIKV [54].

CPE based microneutralization assay

A cytopathic effect (CPE) based neutralization assay was used to determine neutralizing capacity of serum. At the time of the assay, serum and ZIKV aliquots were thawed. Two-fold dilution series of the serum was mixed with ZIKV (200 TCID50) in DMEM 2%FBS. Titers were determined by inoculating 100 μL of the preincubated serum/ZIKV mixture to freshly confluent monolayers of Vero cells grown in 96-well plates. The plates were incubated under 5% CO2 for 5 days at 36°C ± 2°C, before visual observation of the cell monolayer under a microscope for the presence of CPE resulting from viral infection. The neutralization titer was reported as the highest serum dilution that lacked visible CPE.

Renilla–Glo Luciferase assay system and CellTiter-Glo cell toxicity detection system

The Renilla–Glo Luciferase assay system (Promega, USA, catalog number E2720) and the CellTiter-Glo detection system (Promega, USA; catalog number G7570) was used per manufacturer’s instructions for chemiluminescent detection. Tissue-culture treated 384-well white opaque bottom plates (Corning, 3570) were used.

Briefly, assay plates were left to come to ambient temperature (room temperature, 20–22°C) for 15 min. Substrate was removed from -20°C and mixed to buffer (stored at room temperature for up to 3 months, or long-term at -20°C) at 1:100 dilution. Substrate/buffer was added to the assay plates in a biosafety cabinet and incubated for 15 min at room temperature in the dark. The plates were read within 60 min.

Electronic pipettes

These procedures were carried out using Thermo Scientific pipettes, including E1-Cl iptip electronic 8 channel of various volumes, E1-Cl iptip Equalizer 38430 with 8 and 12 channels and E1-Cl iptip Equalizer 384125 with 8 channels. All pipettes were used with current software versions and were calibrated yearly. Pipettes of equivalent accuracy and precision can be substituted.
Chemiluminescence reader
The EnSpire Alpha Multimode Plate Reader (model 2300 or 2390) by Perkin Elmer was used for chemiluminescent detection. Equivalent readers may be used.

Data conversion to titers
Initially, JMP12 and JMP13 were also used with a custom script to generate 4PL curves. GraphPad Prism version 7 or 8 was used for the log_{10} EC_{50} and EC_{50} titer generation during assay development. In brief, serum serial dilutions are transformed to log_{10}. Relative luciferase units are plotted against the log_{10} serum dilutions. A non-linear regression curve fit is performed with the lower asymptote constrained to 0.

Final optimized parameters of the Z-RVP-384 assay
Lab Protocol can be found [here](https://dx.doi.org/10.17504/protocols.io.bscpnavn)
(1) Sera from human, mouse, rabbit, or non-human primate, are heat-inactivated (HI) at 56˚C for 30 min and then serially diluted in assay media. (2) Serially diluted HI-serum is then transferred to a white tissue-culture treated 384-well flat bottom plate in a final volume of 7.5 μL. (3) Z-RVP particles are added (7.5 μL volume and Z-RVP concentration optimized by lot) and (4) the plate is incubated at 37˚C for 60 min in a 5% CO_{2} humidified incubator to allow neutralization. (5) After the neutralization step Vero cells are added to the 384-well plates at 4,625 cells per well in 15 μL volume and (6) incubated at 37˚C for 72 hrs in a 5% CO_{2} humidified incubator. RVPs that were not neutralized are able to infect cells and produce Renilla luciferase. (7) To detect the Renilla luciferase activity in the cells, the plates are equilibrated to room temperature for 15 min, and then incubated with Renilla-Glo™ Luciferase reagent according to manufacturer’s instructions (Promega, Madison, WI). Chemiluminescence is read with an EnSpire chemiluminescence reader (Perkin Elmer, USA) or equivalent as relative luciferase units (RLU), followed by (8) data conversion to neutralization titers (EC_{50} or log_{10}EC_{50}). Neutralization titer is expressed as inverse of the serum dilution which reduces the relative luciferase activity by 50%. The optimal serum input dilution is 1:8 in assay media for the standard assay and is adjusted 2-fold with the addition of the RVP reagent volume (to 1:16) and a further 2-fold with the addition of the cell suspension to 1:32 as the lowest serum input dilution presented here. To generate Effective Concentration 50% (EC_{50}) titers, non-linear regression curves are fit to relative luciferase units plotted against serum dilution (in log_{10}) with the lower asymptote constrained to 0 using GraphPad PRISM (version 7 or higher). The log_{10}EC_{50} titers are normally distributed, the EC_{50} titers are not.

Statistical analyses
Log_{10}-transformed EC_{50} titers were used for all statistical tests as they were normally distributed. Group comparisons were carried out using One-Way ANOVA of means with Tukey’s multiple comparison in GraphPad PRISM (version 7 or 8) or JMP13 (SAS, USA).

For the interleaved assay, the mean (AVG), SD and CV (of the mean) for each signal (max, mid, min explained under Signal stability section) on each plate. The CV takes into account the duplicates wells that will be used in the assay (CV = \frac{SD}{AVG}) [35]. For the mid-signal wells the % activity relative to the means of the max and mid signals was calculated per plate (%Activity = \frac{\text{AVG(mid)} - \text{AVG(min)}}{\text{AVG(max)} - \text{AVG(min)}} \times 100) [35]. The mean and SD for the mid-signal percent activity values were calculated per plate. The Signal Window (SW) was calculated for each plate.
\[ SW = \left( \frac{\text{AVG}(\text{max})}{n} - 3 \times \frac{SD(\text{max})}{\sqrt{n}} \right) \times \left( \frac{\text{AVG}(\text{min})}{n} + 3 \times \frac{SD(\text{min})}{\sqrt{n}} \right) \], where \( n \) is the number of replicates of the test substance that will be used in the assay \( (n = 2) \) [35]. The \( Z' \) factor \( (Z') \) was calculated for each plate using the formula:

\[ Z' = 1 - \frac{3(\text{signal} + \text{error})}{|\mu - \mu_n|} \] [35].

To assess the robustness of the assay, the total variation of the assay was assessed in JMP version 13. To determine which factors have the greatest influence on assay variability a variance component analysis was conducted in JMP (SAS, USA). In the variance component analysis, the SD was calculated as the square root of each variance component estimate. The \% GCV was calculated by the formula:

\[ \% \text{GCV} = 100 \% \left( \frac{\text{ln}(10)^{SD}}{1} \right) \] [37].

To assess the level of correlation between Z-RVP-384 and PRNT titers, a Spearman correlation was determined in R version 3.2.2.

### Plate acceptance criteria

We developed several acceptance criteria based on Z-RVP-384 assay performance characterization: required assay signal (RLU) and positive and negative control ranges. Maximum signal (RLU) of the Z-RVP-384 assay must be greater than 100,000 RLU and less than 10,000,000 RLU, the detection limit of the EnSpire Alpha chemiluminescence readers we used (Perkin Elmer technical guidance). Acceptance ranges for the positive and negative serum controls included on each plate were established as mean log_{10}EC_{50} ± 3x SD for the positive control and mean log_{10}EC_{50} + 2x SD for the negative control. All samples on a failed plate must be retested.

### Sample titer acceptance criteria

The fit of the non-linear dose response curve to the observed data points is assessed by % FE with an upper limit of 40% for all sera above the LLOQ. Every sample that fails one or more titer acceptance criteria is retested. The sample is considered negative for ZIKV-neutralizing antibodies when the log_{10}EC_{50} titer is below the species-specific serum matrix cut-off, which also serves as the LLOQ and the LOD (Table 3). The ULOQ for the standard assay (1:8 serum dilution in assay media as input) is 5.00 log_{10}EC_{50}. Any sample > ULOQ is re-tested using a pre-dilution of 1:200 or greater.

We observed a 1% disagreement rate between accepted titers when measuring 429 samples independently by two operators, indicating that the acceptance criteria contribute to a high level of titer consistency.

### Flavivirus-screening assay

The Flavivirus Screening assay was developed in collaboration with Luminex\textsuperscript{©} Corp (Austin, TX, USA) at Ampersand Biosciences (Lake Clear, NY, USA). Serum samples were diluted 1:2,000-fold in sample dilution buffer (PBS, 0.05% ProClin 300). 30 \( \mu \)L of the diluted sample was transferred to a 96-well plate including negative, low and high positive controls. 10 \( \mu \)L diluted multiplexed serological panel bead mix (1500 beads per antigen) was added to each sample followed by a 60-minute incubation (room temperature, in the dark, orbital shaker 850 rpm). The beads were washed three times with 100 \( \mu \)L of assay buffer (PBS, 0.05% Tween 20, 0.05% ProClin 300). 40 \( \mu \)L Anti-IgG PE was added to each well and incubated 30 min at room temperature with shaking. The beads were washed three times as above and resuspended in 100 \( \mu \)L assay buffer and analyzed using a Luminex\textsuperscript{©} 200\textsuperscript{®}. Greater than 35 beads per antigen were read and plates accepted based on control ranges and IgG bead having >20,000 median fluorescent intensity (MFI).
Supporting information

S1 File. Animal study design.
(DOCX)

S1 Checklist. The ARRIVE guidelines 2.0: Author checklist.
(PDF)

Acknowledgments

We would like to acknowledge Srisowmya Sanisetty, Jeanne Dudek, Swati Mukherjee, Christina DeMaso, and Allan Parker for technical support, Ginger Young, Subash Das and Shylah Wylie for in-life study support, and the ZIK101 clinical study teams and participants. The authors thank Keith Veitch (keithveitch communications, Amsterdam, the Netherlands) for providing medical writing support for the first draft of the manuscript. We would like to thank the Integral Molecular team for their scientific support on Z-RVP production and QC.

Author Contributions

Conceptualization: Kelly Bohning, Stephanie Sonnberg, Hui-Ling Chen, Timothy Powell, Greg Hather, Hetal K. Patel, Hansi J. Dean.

Formal analysis: Kelly Bohning, Stephanie Sonnberg, Hui-Ling Chen, Melissa Zahralban-Steele, Timothy Powell, Greg Hather.

Methodology: Kelly Bohning, Hui-Ling Chen, Melissa Zahralban-Steele.

Supervision: Hetal K. Patel, Hansi J. Dean.

Writing – original draft: Kelly Bohning, Stephanie Sonnberg, Hetal K. Patel, Hansi J. Dean.

Writing – review & editing: Stephanie Sonnberg, Hetal K. Patel, Hansi J. Dean.

References

1. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952; 46(5):509–20. https://doi.org/10.1016/0035-9203(52)90042-4 PMID: 12995440

2. Petersen LR, Jamieson DJ, Powers AM, Honein MA. Zika Virus. N Engl J Med. 2016; 374(16):1552–63. https://doi.org/10.1056/NEJMra1602113 PMID: 27028561

3. Waddell LA, Greig JD. Scoping Review of the Zika Virus Literature. PLoS One. 2016; 11(5):e0156376. https://doi.org/10.1371/journal.pone.0156376 PMID: 27244249

4. Rice ME, Galang RR, Roth NM, Ellington SR, Moore CA, Valencia-Prado M, et al. Vital Signs: Zika-Associated Birth Defects and Neurodevelopmental Abnormalities Possibly Associated with Congenital Zika Virus Infection—U.S. Territories and Freely Associated States, 2018. MMWR Morb Mortal Wkly Rep. 2018; 67(31):858–67. https://doi.org/10.15585/mmwr.mm6731e1 PMID: 30091967

5. Van Gessel Y, Klade CS, Putnak R, Fornica A, Krassaesub S, Spruth M, et al. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(R)) induced neutralizing antibody titers. Vaccine. 2011; 29(35):5925–31. https://doi.org/10.1016/j.vaccine.2011.06.062 PMID: 21723353

6. Julander JG, Trent DW, Monath TP. Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine. 2011; 29(35):6008–16. https://doi.org/10.1016/j.vaccine.2011.06.034 PMID: 21718741

7. Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg. 2005; 72(2):189–97. PMID: 15741556

8. Phillipotts RJ, Stephenson JR, Porterfield JS. Passive immunization of mice with monoclonal antibodies raised against tick-borne encephalitis virus. Brief report. Arch Virol. 1987; 93(3–4):295–301. https://doi.org/10.1007/BF01310985 PMID: 3827600
9. Collaborative Group for Studies of Yellow Fever V. A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015; 110(6):771–80. https://doi.org/10.1590/0074-02760150150176 PMID: 26517656

10. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010; 28(3):632–49. https://doi.org/10.1016/j.vaccine.2009.09.098 PMID: 19808209

11. Hurtado-Monzon AM, Cordero-Rivera CD, Farfan-Morales CN, Osuna-Ramos JF, De Jesus-Gonzalez LA, Reyes-Ruiz JM, et al. The role of anti-flavivirus humoral immune response in protection and pathogenesis. Rev Med Virol. 2020; e2100. https://doi.org/10.1002/rmv.2100 PMID: 32101633

12. Dowd KA, Ko SY, Morimoto KM, Yang ES, Pelc RS, Desrosiers CR, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016; 354(6309):237–40. https://doi.org/10.1126/science.aad9137 PMID: 27708058

13. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA Vaccines Protect against Zika Virus Infection. Cell. 2017; 169(1):176.

14. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016. https://doi.org/10.1126/science.aah6157 PMID: 27492477

15. Baldwin WR, Livengood JA, Giebler HA, Stovall JL, Boroughs KL, Sonnberg S, et al. Purified Inactivated Yellow Fever Virus Vaccine: Lessons Learned from the 2004 Outbreak in Haiti. Vaccine. 2005; 23(21):2478–84. https://doi.org/10.1016/j.vaccine.2005.03.062 PMID: 15977968

16. Espinosa D, Montenegro D, Varghese M, Wang C, Li S, Tsuchihashi T, et al. Passive Transfer of Immune Sera Induced by a Zika Virus-Like Particle Vaccine Protects AG129 Mice Against Lethal Zika Virus Challenge. EBioMedicine. 2018; 27:61–70. https://doi.org/10.1016/j.ebiom.2017.12.010 PMID: 29269041

17. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010; 17(7):1055–65. https://doi.org/10.1128/CVI.00131-10 PMID: 20463105

18. World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. Geneva: World Health Organization; 2005.

19. Maeda A, Maeda J. Review of diagnostic plaque reduction neutralization tests for flavivirus infection. J Vet Med Sci. 2010; 72(1):1–5. https://doi.org/10.1292/jvms.09-0140

20. Mattia K, Puffer BA, Williams KL, Gonzalez R, Murray M, Siuzas E, et al. Dengue reporter virus particles for measuring antibodies against each of the four dengue serotypes. PLoS One. 2011; 6(11):e27252. https://doi.org/10.1371/journal.pone.0027252 PMID: 22096543

21. Garg H, Sedano M, Plata G, Punke EB, Joshi A. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus. J Virol. 2017; 91(20). https://doi.org/10.1128/JVI.00834-17 PMID: 28794019
29. Dow KA, DeMasco CR, Pelc RS, Speer SD, Smith ARY, Goo L, et al. Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. Cell Rep. 2016; 16(6):1485–91. https://doi.org/10.1016/j.celrep.2016.07.049 PMID: 27481466

30. Ansarah-Sobrinho C, Nelson S, Jost CA, Whitehead SS, Pierson TC. Temperature-dependent production of pseudoinfectious dengue virus particles by complementation. Virology. 2008; 381(1):67–74. https://doi.org/10.1016/j.virol.2008.08.021 PMID: 18801552

31. Mukherjee S, Pierson TC, Dowd KA. Pseudo-infectious reporter virus particles for measuring antibody-mediated neutralization and enhancement of dengue virus infection. Methods Mol Biol. 2014; 1138:75–97. https://doi.org/10.1007/978-1-4939-0348-1_6 PMID: 24969332

32. Whitbeck JC, Thomas A, Kadash-Edmondson K, Grinyo-Escure A, Stafford LJ, Cheng C, et al. Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications. PLoS Negl Trop Dis. 2020; 14(11):e0008730. https://doi.org/10.1371/journal.pntd.0008730 PMID: 33206639

33. Bailey M. JMP software: Custom Design of Experiments Course Notes.: SAS Institute Inc.; 2014 20 March.

34. Ilya Ravkin VT, Aaron D, Nelson, Michael A. Zarowitz, Matthew Hoopes, Yuli Verhovsky, Gregory Ascue, et al. Multiplexed high-throughput image cytometry using encoded carriers. SPIE. 2004;5322.

35. Iversen P, Beck B, Chen Y, Dere W, Devanarayan V, Eastwood B, et al. HTS Assay Validation. First Edition Crossing the Line. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2012.

36. ICH Q2 Validation of analytical procedures: text and methodology. In: Teasdale A, Elder D, Nims R, editors. ICH Quality Guidelines: An Implementation Guide2017.

37. Anonymous. USP Chapter (1033) Biological Assay Validation. United States Pharmacopoeia Convention; 2017.

38. Osuna CE, Whitney JB. Nonhuman Primate Models of Zika Virus Infection, Immunity, and Therapeutic Development. J Infect Dis. 2017; 216(suppl_10):S928–S34. https://doi.org/10.1093/infdis/jx540 PMID: 29267926

39. Dejnirattrisai W, Supasa P, Wongwiwat W, Rouvins ki A, Barba-Spaeth G, Duangchinda T, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol. 2016; 17(9):1102–8. https://doi.org/10.1038/ni.3515 PMID: 27339099

40. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016; 353(6301):823–6. https://doi.org/10.1126/science.aaf8505 PMID: 27417494

41. Han HH DC, Acosta CJ. Safety and immunogenicity of a purified inactivated Zika virus vaccine (PIZV) candidate in healthy adults; a randomized, observer-blind phase 1 clinical trial. Lancet Infectious Disease. 2021; Accepted.

42. Mattiuzzo G, Knezevic I, Hassall M, Ashall J, Myhill S, Faulkner V, et al. Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody. NPJ Vaccines. 2019; 4:42. https://doi.org/10.1038/s41541-019-0135-3 PMID: 31632743

43. Organization WRotAPA H. PLISA Health Information Platform for the Americas: Cases of Zika virus disease, by country or territory.

44. WHO. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. Geneva, Switzerland: WHO; 2016.

45. Barrett ADT. Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation. NPJ Vaccines. 2018; 3:24 https://doi.org/10.1038/s41541-018-0061-9 PMID: 29900012

46. Maslow JN. Zika Vaccine Development-Current Progress and Challenges for the Future. Trop Med Infect Dis. 2019; 4(3). https://doi.org/10.3390/trmd19040194 PMID: 31337115

47. Abbink P, Larocca RA, Visitsunthorn K, Boyd M, De La Barrera RA, Gromowski GD, et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med. 2017; 9(420). https://doi.org/10.1126/scitranslmed.aao4193 PMID: 29237759

48. Golding H, Khurana S, Zaitseva M. What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. Cold Spring Harb Perspect Biol. 2018; 10(4). https://doi.org/10.1101/cshperspect.a028902 PMID: 28348035

49. Gruber MF, Farizzo KM, Pratt RD, Fink DL, Finn TM, Krause PR, et al. Clinical Development Strategies and Considerations for Zika Vaccine Licensure. J Infect Dis. 2017; 216(suppl_10):S964–S70. https://doi.org/10.1093/infdis/jx433 PMID: 29267913

50. Beasley DWC, Brasel TL, Comer JE. First vaccine approval under the FDA Animal Rule. NPJ Vaccines. 2016; 1:16013. https://doi.org/10.1038/npjvaccines.2016.13 PMID: 29263655
51. Young G, Bohning KJ, Zahralban-Steele M, Hather G, Tadepalli S, Mickey K, et al. Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection. Sci Rep. 2020; 10(1):3488. https://doi.org/10.1038/s41598-020-60415-6 PMID: 32103097

52. Breitbach ME, Newman CM, Dudley DM, Stewart LM, Aliota MT, Koenig MR, et al. Primary infection with dengue or Zika virus does not affect the severity of heterologous secondary infection in macaques. PLoS Pathog. 2019; 15(8):e1007766. https://doi.org/10.1371/journal.ppat.1007766 PMID: 31369649

53. Ye Q, Liu ZY, Han JF, Jiang T, Li XF, Qin CF. Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. Infect Genet Evol. 2016; 43:43–9. https://doi.org/10.1016/j.meegid.2016.05.004 PMID: 27156653

54. Renner M, Flanagan A, Dejnirattisai W, Puttikhunt C, Kasinrerk W, Supasa P, et al. Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. Nat Immunol. 2018; 19(11):1248–56. https://doi.org/10.1038/s41590-018-0227-7 PMID: 30323338